Entry |
|
Name |
Mutation-inactivated TP53 to transcription
|
Definition |
TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK) |
Expanded |
7157v1 // (1026,1647,4616,10912,581,578,1643,51426) |
Class |
|
Type |
Variant
|
Pathway |
|
Disease |
H00048 | Hepatocellular carcinoma |
H00004 | Chronic myeloid leukemia |
H00014 | Non-small cell lung cancer |
|
Gene |
7157 | TP53; tumor protein p53 |
1026 | CDKN1A; cyclin dependent kinase inhibitor 1A |
1647 | GADD45A; growth arrest and DNA damage inducible alpha |
4616 | GADD45B; growth arrest and DNA damage inducible beta |
10912 | GADD45G; growth arrest and DNA damage inducible gamma |
581 | BAX; BCL2 associated X, apoptosis regulator |
578 | BAK1; BCL2 antagonist/killer 1 |
1643 | DDB2; damage specific DNA binding protein 2 |
51426 | POLK; DNA polymerase kappa |
|
Variant |
|
Reference |
|
Authors |
Kirsch DG, Kastan MB |
Title |
Tumor-suppressor p53: implications for tumor development and prognosis. |
Journal |
|
Reference |
|
Authors |
Fridman JS, Lowe SW |
Title |
Control of apoptosis by p53. |
Journal |
|
Reference |
|
Authors |
Tokino T, Nakamura Y. |
Title |
The role of p53-target genes in human cancer. |
Journal |
|
Reference |
|
Authors |
Reed SM, Quelle DE |
Title |
p53 Acetylation: Regulation and Consequences. |
Journal |
|
LinkDB |
|